Antibodies from individuals who survived an infection with avian influenza may effectively neutralize H5N1 strains, according to research from the National Institute of Allergy and Infectious Diseases, in Bethesda, Md; the Hospital for Tropical Diseases, in Ho Chi Minh City, Vietnam; and the Institute for Research in Biomedicine, in Bellinzona, Switzerland (Simmons CP et al. PLoS Med. 2007;4:e178).
Anti-H5N1 human monoclonal antibodies administered to mice subsequently challenged with H5N1 caused a statistically significant reduction in pulmonary virus titer, reduced associated inflammation in the lungs, and restricted extrapulmonary dissemination of the virus. The antibodies also protected the mice from lethal doses of H5N1 when given up to 72 hours after infection.
Hampton T. H5N1 Antibodies. JAMA. 2007;298(1):32. doi:10.1001/jama.298.1.32-c